From 17 May announcement:
Saliva Use Case
The laboratory validation of the saliva samples is currently underway. Pending analysis and results of the saliva samples, an updated CE regulatory submission will be made to amend the Instruction For Use (IFU) of the current EuGeni SARS-CoV-2 ART to include oral saliva sampling. The test and all components remain the same. AnteoTech remains on track to submit the update to the CE Mark in June 2021, pending results.
Ann: AnteoTech raises $8.0m in strongly supported SPP, page-75
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $54.30M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $8.816K | 408.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1278507 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 299817 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| ADO (ASX) Chart |